Concepedia

Ruji Yao

RY

Statistics

Publications

14

Citations

1.3K

H-Index

12

Active since

2000

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

MSD (Belgium)

MSD (Italy)

Hôpital Lapeyronie

MSD (Switzerland)

Ruji Yao is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in pharmacotherapy, pharmacology, and medicine.

Publications per year

2000–2023

14

Publications

14

A Randomized, Double–Blind Trial Comparing Pegylated Interferon Alfa–2B to Interferon Alfa–2B As Initial Treatment for Chronic Hepatitis C

Karen L. Lindsay, Christian Trépo, Tobias Heintges et al. · Hepatology · 2001 · 665 citations

, , +15

Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents

Michael S. Blaiss, Jennifer Maloney, Hendrik Nolte et al. · Journal of Allergy and Clinical Immunology · 2011 · 243 citations

, , +14

The impact of interferon plus ribavirin on response to therapy in black patients with chronic hepatitis C

John G. McHutchison, Thierry Poynard, Stephen Pianko et al. · Gastroenterology · 2000 · 186 citations · Full text

, , +12

A placebo-controlled study of the nasal decongestant effect of phenylephrine and pseudoephedrine in the Vienna Challenge Chamber

Friedrich Horak, Petra Zieglmayer, René Zieglmayer et al. · Annals of Allergy Asthma & Immunology · 2009 · 64 citations

, , +8

Efficacy and safety of golimumab as add-on therapy to disease-modifying antirheumatic drugs: results of the GO-MORE study

Bernard Combe, Bhaskar Dasgupta, Ingrid Louw et al. · Annals of the Rheumatic Diseases · 2013 · 31 citations · Full text

, , +11

1–5 of 14